Anaphylaxis: Initial Emergency Treatment by Nurses (Adult & Pediatric)

Clinical Decision Support Tool

Contents

1.0 Site Applicability .................................................................................................................. 2
2.0 Scope of Practice Limits and Conditions ................................................................. 2
  2.1 Conditions on Practice .................................................................................................... 2
    A. Administration of epinephrine ...................................................................................... 2
    B. Administration of oxygen ......................................................................................... 2
3.0 Policy Statement ............................................................................................................. 2
4.0 Need to Know and Key Points ...................................................................................... 3
5.0 Assessment and Nursing Diagnosis of Anaphylaxis ..................................................... 3
6.0 Anaphylaxis Response Kit Contents ............................................................................. 6
  Client Owned Auto-injector of Epinephrine .................................................................... 6
7.0 Injection Location Considerations .................................................................................. 6
8.0 Intervention: Initial Emergency Treatment of Anaphylaxis ........................................ 7
9.0 Client / Family Education .............................................................................................. 8
10.0 Documentation ................................................................................................................ 8
11.0 Reporting ........................................................................................................................ 8
References ............................................................................................................................. 9
Appendix A: Common Triggers for Anaphylaxis ............................................................... 11
Appendix B: EPINEPHrine 1mg/ml Dose by Age Table ................................................... 12
1.0 Site Applicability

If anaphylaxis is suspected, based upon clinical presentation and possible exposure to a trigger, treatment should be provided as outlined in this document.

All Acute, Community, Long Term Care sites and non-hospital settings

\textit{Exception:} when an alternate practice standard/procedure, clinical decision support tool or medical order is in effect for initial emergency treatment of anaphylaxis.

\textbf{Note:} All nurses (RN, RPN and LPN) who immunize without an order must follow the Decision Support Tools (DST) – BC Communicable Disease Control Manual, Chapter 2: Immunization; Part 3 Management of Anaphylaxis in a Non-Hospital Setting established by the BC Centre for Disease Control (BCCDC). The clinical direction in both of these documents is identical.

In this document \textit{client} refers to patient, client or resident.

2.0 Scope of Practice Limits and Conditions

This decision support tool is intended for use by nurses.

Following an assessment and nursing diagnosis of anaphylaxis, Registered Nurses (RN), Registered Psychiatric Nurses (RPN) and Licensed Practical Nurses (LPN) may carry out the initial emergency management of anaphylaxis:

- regardless of the causative agent;
- without an order;
- across all healthcare settings (i.e. hospital and non-hospital)

2.1 \textbf{Conditions on Practice}

\textbf{A. Administration of epinephrine}

Prior to administering epinephrine for the emergency management of anaphylaxis:

1) RN, RPN and LPN must follow this decision support tool.

2) RPN and LPN must successfully complete additional education \[\text{Anaphylaxis Initial Emergency Treatment by Nurses (Adult & Pediatric)}. \text{Available on Learning Hub}\]

This education is recommended for RNs.

\textbf{B. Administration of oxygen}

Health Authority/employer practice limits may apply.

If available in the practice setting, prior to initiating oxygen therapy:

1) LPNs must follow a decision support tool and complete additional education.

3.0 \textbf{Policy Statement}

Clients who have been treated for anaphylaxis must have immediate follow up by a physician or Nurse Practitioner.

In the community, long term care and ambulatory settings, clients who have been treated for anaphylaxis must be transferred to hospital via ambulance.
4.0 Need to Know and Key Points

Anaphylaxis occurs with exposure to a trigger (see Appendix A) in a susceptible individual. Onset of symptoms usually occurs in minutes but can occur hours after exposure to a trigger. Death from anaphylaxis may occur as a result of severe respiratory complications, cardiovascular collapse, or both.

Early administration of intramuscular (IM) Epinephrine is first line treatment for anaphylaxis to prevent death and there is no known equivalent substitute. There is no contra-indication to epinephrine administration in anaphylaxis.

Epinephrine:
- Acts on smooth muscle of the bronchial tree reducing bronchospasm
- Counteracts histamine-induced vasodilation
- Increases cardiac output
- Reduces histamine release

Note: Diphenhydramine (Benadryl) is NOT INDICATED in anaphylaxis.

Antihistamines are not indicated as initial first line treatment in the emergency management of anaphylaxis as there is no effect on respiratory or cardiovascular symptoms and they are of little clinical importance in life-threatening anaphylaxis based on current evidence. H1 antihistamines (e.g. Benadryl) relieve localized and less severe systemic allergic reactions and the only useful clinical effect is the improvement of itch and hives.4, 13, 14

5.0 Assessment and Nursing Diagnosis of Anaphylaxis

Early recognition of anaphylaxis is essential to ensure timely intervention.

Assess the client for signs and symptoms of anaphylaxis. These generally involve two or more body systems. See Table 1 for clinical scenarios and body systems involved.

IMPORTANT: Anaphylaxis can occur without presence of hives.

Table 1: Clinical Scenarios and Body Systems Involved with Anaphylaxis.

<table>
<thead>
<tr>
<th>Clinical Scenario</th>
<th>(1) No Clear Trigger</th>
<th>(2) Suspected Trigger (new food, drug or immunization)</th>
<th>(3) Accidental Exposure to Known Allergen (Same as column 2 or ↓ BP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGNS &amp; SYMPTOMS</td>
<td>• Skin/mucosal or both + Plus at least one of the following: • Respiratory Compromise • Reduced Blood Pressure or Associated Symptoms</td>
<td>TWO OR MORE of the following: • Skin/mucosal • Respiratory Compromise • Reduced Blood Pressure or Associated S/S • Persistent GI</td>
<td>REDUCED BLOOD PRESSURE ONLY • Child – Low Systolic or decrease greater than 30% • Adult – Systolic 90 or decrease greater than 30% from baseline</td>
</tr>
</tbody>
</table>

Onset Minutes to Hours

Refer to Image 1: World Allergy Organization Anaphylaxis Guideline Poster on page 4 of this document for a detailed description of signs and symptoms to inform the assessment and nursing diagnosis of anaphylaxis.
Anaphylaxis must be distinguished from fainting (vasovagal syncope) and anxiety (panic attack). See Table 2: Signs and Symptoms of Anaphylaxis versus Fainting and Anxiety.
Table 2: Signs and Symptoms of Anaphylaxis versus Fainting and Anxiety

<table>
<thead>
<tr>
<th></th>
<th>Anaphylaxis</th>
<th>Fainting</th>
<th>Anxiety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definitions</strong></td>
<td>A potentially life threatening allergic reaction that is rapid in onset and progression of symptoms.</td>
<td>Temporary unconsciousness caused by diminished blood supply to the brain due to painful stimuli or emotional reaction.</td>
<td>Protective physiological state recognized as fear, apprehension, or worry</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>• rapid onset and progression of symptoms</td>
<td>• sudden onset</td>
<td>• sudden onset</td>
</tr>
<tr>
<td></td>
<td>• occurs minutes to hours after exposure to trigger</td>
<td>• occurs before, during or shortly after trigger (e.g. sight of the needle)</td>
<td>• occurs before, during, or shortly after trigger (e.g. sight of the needle)</td>
</tr>
<tr>
<td></td>
<td>• recovery dependent on response to treatment</td>
<td>• recovery occurs within 1-2 minutes</td>
<td>• recovery generally occurs within 1-2 minutes</td>
</tr>
<tr>
<td><strong>Skin/Mucosal</strong></td>
<td>• localized subcutaneous (or sub mucosal) swelling and tingling to face and mouth</td>
<td>• pale</td>
<td>• pale</td>
</tr>
<tr>
<td></td>
<td>• hives – may be delayed</td>
<td>• excessive perspiration</td>
<td>• excessive perspiration</td>
</tr>
<tr>
<td></td>
<td>• warm, itchy, red and blotchy</td>
<td>• cold, clammy</td>
<td>• cold, clammy</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td>• labored breathing - hoarse voice, throat tightness, rapid breathing, wheezing, coughing, nasal flaring, nasal and chest congestion</td>
<td>• breathing normal or shallow, irregular and labored</td>
<td>• breathing rapid and shallow (hyperventilation)</td>
</tr>
<tr>
<td></td>
<td>• rhinitis (stuffy or runny nose, itchy watery eyes and sneezing)</td>
<td></td>
<td>• breath-holding in children</td>
</tr>
<tr>
<td></td>
<td>• shortness of breath, stridor, retractions, chest pain and cyanosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>• weak and rapid pulse</td>
<td>• slow, steady pulse</td>
<td>• rapid pulse</td>
</tr>
<tr>
<td></td>
<td>• hypotension alone after an exposure can represent anaphylaxis</td>
<td>• decreased systolic and diastolic</td>
<td>• normal or elevated systolic</td>
</tr>
<tr>
<td></td>
<td>• hypotension is less common in children</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• shock</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>• nausea, vomiting, diarrhea</td>
<td>• nausea</td>
<td>• nausea</td>
</tr>
<tr>
<td></td>
<td>• abdominal pain or cramping</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• dysphagia (difficulty swallowing)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• drooling in children</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>• anxious or feeling of “impending doom”</td>
<td>• fearfulness</td>
<td>• fearfulness</td>
</tr>
<tr>
<td></td>
<td>• sudden lack of energy (lethargy) in children</td>
<td>• light-headedness</td>
<td>• light-headedness</td>
</tr>
<tr>
<td></td>
<td>• quietness or sleepiness in children</td>
<td>• dizziness</td>
<td>• dizziness</td>
</tr>
<tr>
<td></td>
<td>• headache, light-headedness or dizziness</td>
<td>• numbness, weakness</td>
<td>• numbness, weakness</td>
</tr>
<tr>
<td></td>
<td>• decreased level of consciousness</td>
<td>• sometimes accompanied by brief clonic seizure activity</td>
<td>• tingling around lips and spasm in the hands and feet associated with hyperventilation</td>
</tr>
<tr>
<td></td>
<td>• uterine cramps</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Bolded text indicates symptoms specific to pediatric clients.
6.0 Anaphylaxis Response Kit Contents

- Copy of this Decision Support Tool
- 4 ampoules of EPINEPHrine 1mg/mL
- 4 – 1 mL syringes
- Needles (25 to 27 gauge)
  - 4 - 1 inch
  - 4 - 1½ inch
- Alcohol swabs

Check medication vials and equipment. Replace if outdated.

**Client Owned Auto-injector of Epinephrine**

A client’s own auto-injector of epinephrine may be used to administer epinephrine in situations where a delay in administration of epinephrine may occur (e.g. kit not readily available). Clinical judgement is required.

*Note:* EpiPen® delivers 0.3 mg of epinephrine and EpiPen Junior® delivers 0.15 mg of epinephrine.

7.0 Injection Location Considerations

The correct site of intramuscular (IM) administration of epinephrine is ALWAYS the vastus lateralis located at the middle third of the *lateral thigh* [See image 1].

**Image 1: Vastus Lateralis Injection Site**

*Notes:*

- If immunization/medication has been administered to both legs, give epinephrine IM at least 2.5 cm (1 inch) from original injection site.
- Administration of epinephrine through the clothing is acceptable in emergency situations.
8.0 Intervention: Initial Emergency Treatment of Anaphylaxis

**ASSESS** client for signs & symptoms of anaphylaxis
Circulation, Airway, Breathing (CAB)  Skin, Mental Status and GI

Remove/Stop the offending agent/drug (if possible)

---

**ADMINISTER**
EPINEPHrine Intramuscular (IM) Only

<table>
<thead>
<tr>
<th>Adults (14 years and older)</th>
<th>Children under 14 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 mg (of 1 mg/mL)</td>
<td>0.01 mg/kg (of 1mg/mL)</td>
</tr>
<tr>
<td>IM vastus lateralis</td>
<td>IM vastus lateralis</td>
</tr>
</tbody>
</table>

**CALL** Code Blue or 911

**RE-ASSESS** CAB

Place in Recumbent Position / Elevate Legs (if possible)

**ADMINISTER** Oxygen for Hypoxia (if available)
Goal: SpO2 above 92%

**CONTINUOUS OBSERVATION**
VITAL SIGNS Q5 Minutes until Transfer of Care

**REPEAT** EPINEPHrine (IM) Q5 Minutes PRN x 2 doses
for ongoing signs and symptoms of anaphylaxis
(to a maximum of 3 total doses)

<table>
<thead>
<tr>
<th>Adults (14 years and older)</th>
<th>Children under 14 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 mg (of 1 mg/mL)</td>
<td>0.01 mg/kg (of 1mg/mL)</td>
</tr>
<tr>
<td>IM vastus lateralis</td>
<td>IM vastus lateralis</td>
</tr>
</tbody>
</table>

**INITIATE** IV Access (if possible)
**DO NOT ADMINISTER** EPINEPHrine via IV Route

**DOCUMENT & PROVIDE HANDOVER** to CODE TEAM or PARAMEDICS
- Time of onset and nature of symptoms
- Interventions provided including timing and amount of epinephrine
- Response to treatment
9.0 Client / Family Education

Clients who have experienced anaphylaxis and their families should receive education including:

- Information on anaphylaxis being a potentially life threatening allergic reaction
- Avoiding triggers
- The emergency steps to take in case of anaphylaxis:
  - Carry your prescribed epinephrine auto-injector
  - Administer prescribed epinephrine auto-injector immediately
  - If in a hospital, long term care home or other institution: summon help
  - If in the community, or at home: call an ambulance
- Follow up with your physician, nurse practitioner, allergist or other appropriate resource to:
  - Develop an anaphylaxis action plan including self-administration of epinephrine
  - Obtain medical identification (e.g. MedicAlert®)
  - Undergo testing to confirm triggers
  - Explore ways that sensitivities to triggers may be reduced

Suggested client teaching resources:
- Health Link BC. (2018) Severe Allergic Reaction (Anaphylaxis)

10.0 Documentation

- Document the following in the health record:
  - Assessment
  - Nursing diagnosis of the condition
  - Interventions carried out
  - Client’s response
  - Follow-up actions, transfer of care and client teaching
- Enter client allergy status as per employer policies to ensure communication to other providers.

11.0 Reporting

Suspected anaphylaxis adverse reactions related to drug or immunization administration are reported as required by employer policy:

- Patient Safety Learning System (PSLS) or equivalent (as required)
- Long Term Care settings must report adverse event to licensing body (as required)
- If the trigger for anaphylaxis is the result of an immunization, complete the following:
  - BCCDC Worksheet for Events Managed as Anaphylaxis Following Immunization
  - BCCDC Adverse Event Following Immunization (AEFI) Case Report Form
References


Appendix A: Common Triggers for Anaphylaxis

The true global rate of occurrence of anaphylaxis from all triggers in the general population is unknown because of under-recognition by patients and caregivers and under-diagnosis by healthcare professionals.¹

Numerous nursing and health care activities expose patients to common triggers for anaphylaxis. Below are some selected common triggers for anaphylaxis. Triggers for individuals can vary widely and the below list is not exhaustive.

<table>
<thead>
<tr>
<th>Food</th>
<th>Environment</th>
<th>Medications / Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peanuts</td>
<td>Venom from stinging insects</td>
<td>Antibiotics especially β lactams (including penicillins, cephalosporins, carbapenems)</td>
</tr>
<tr>
<td>Tree nuts</td>
<td>Horse</td>
<td>Non-steroidal anti-inflammatories (including ASA)</td>
</tr>
<tr>
<td>Soy</td>
<td>Latex</td>
<td>Biologic medications including immunizations</td>
</tr>
<tr>
<td>Seafood</td>
<td></td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Shellfish</td>
<td></td>
<td>Radiocontrast media (x-ray dye)</td>
</tr>
<tr>
<td>Milk</td>
<td></td>
<td>Dextran</td>
</tr>
<tr>
<td>Eggs</td>
<td></td>
<td>Substances found in illicit drugs</td>
</tr>
<tr>
<td>Mustard</td>
<td></td>
<td>Blood and Blood Products</td>
</tr>
<tr>
<td>Wheat</td>
<td></td>
<td>Latex Gloves</td>
</tr>
<tr>
<td>Sesame</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix B: EPINEPHrine 1mg/ml Dose by Age Table

NOTE: Use dose by weight whenever possible.

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose in mg</th>
<th>Volume (1 mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-6 months</td>
<td>0.07 mg</td>
<td>0.07 mL</td>
</tr>
<tr>
<td>7-12 months</td>
<td>0.1 mg</td>
<td>0.1 mL</td>
</tr>
<tr>
<td>13 months - 4 years</td>
<td>0.15 mg</td>
<td>0.15 mL</td>
</tr>
<tr>
<td>5 years</td>
<td>0.2 mg</td>
<td>0.2 mL</td>
</tr>
<tr>
<td>6-9 years</td>
<td>0.3 mg</td>
<td>0.3 mL</td>
</tr>
<tr>
<td>10-13 years</td>
<td>0.4 mg</td>
<td>0.4 mL</td>
</tr>
<tr>
<td>Greater than or equal to 14 years</td>
<td>0.5 mg</td>
<td>0.5 mL</td>
</tr>
</tbody>
</table>
Adapted from:
Vancouver Coastal Health & Providence Health Care Professional Practice. (September 2017) Anaphylaxis: Initial Emergency Treatment Decision Support Tool. (Draft)

Developed by:
Paula Araujo, Regional Practice Leader, Clinical Process, Interior Health
Cathy Czechmeister, Lead, Professional Practice Strategy - Nursing, Northern Health
Sheila Gordon-Payne, Lead, Professional Practice Strategy – Nursing, Northern Health
Melina Kason, Practice Consultant, Professional Practice, Island Health

Reviewed by:
Dr. Monika Naus MD FRCPC, Medical Director, Communicable Diseases and Immunization Service, BC Centre for Disease Control
Dr. Scott B. Cameron MD, PhD, FRCPC, Clinical Instructor, Division of Allergy & Immunology, Department of Pediatrics, University of British Columbia
Christine Halpert, Senior Practice Leader, Communicable Diseases and Immunization Service, BC Centre for Disease Control
Stephanie Meier, Public Health Resource Nurse, Communicable Diseases and Immunization Service, BC Centre for Disease Control
BC Provincial Health Authorities Representatives from Fraser Health, Interior Health, Vancouver Coastal Health, Provincial Health Services Authority, Providence Health

Endorsed by:
British Columbia Chief Nursing Officer Council